For Health Care Professionals

Sustained antitumor effect of radiation in combination with LAVURCHIN against human squamous cell carcinoma

LAVURCHIN is not a drug approved as a medicine and cannot be employed for human treatment. In the GLP compliant safety study, inflammation was observed at a high dose administration site, but no toxicity was found. LAVURCHIN has a tumor angiogenesis inhibitory action and anticancer efficacy was observed with respect to several types of human cancer cells transplanted into mice. Furthermore, it has been confirmed that it’s anticancer efficacy is enhanced by radiation irradiation. (Please refer to R&D Library for details)

Types of cancers that exhibit LAVURCHIN induced effects

Breast cancer
Lung cancer
Colorectal cancer
Esophagus cancer
Prostate cancer
Tongue cancer

Anticancer efficacy was also confirmed with respect to squamous cell carcinoma and nasal lymphoma in clinical studies of dogs and cats.

Effectiveness with respect to various types of cancer cells has been confirmed in experiments of small animals with transplanted human cancer cells. Sufficient anticancer efficacy will be expected with the combinational use of LAVURCHIN and radiotherapy for cases in which sufficient anticancer efficacy could not be obtained with conventional radiotherapy.

The realization of a potent anticancer treatment with a lower risk of radiation damage and little drug-induced side effects will be possible.